Document is current

Any future updates will be listed below

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany

Crossref DOI link: https://doi.org/10.1007/s40273-015-0305-8

Published Online: 2015-06-17

Published Print: 2015-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark